Sarah R. Ball

Sarah R. Ball

Auto-generated profile, based on publicly available information

Sarah R. Ball

School of Medical Sciences Faculty of Medicine and Health, and Sydney Nano The University of Sydney Sydney NSW 2006 Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MBMax Baker
Max Baker
NSNirukshan Shanmugam
Nirukshan Shanmugam
CPChi Le Lan Pham
Chi Le Lan Pham
SBSarah R. Ball
Sarah R. Ball
Emma SiereckiEmma Sierecki
Emma Sierecki
MSMargaret Sunde
Margaret Sunde
TIR-domain-containing adapter-inducing interferon-β (TRIF) is an innate immune protein that serves as an adaptor for multiple cellular signalling outcomes in the context of infection. TRIF is activated via ligation of Toll-like receptors 3 and 4. One outcome of TRIF-directed signalling is the activation of the programmed cell death pathway necroptosis, which is governed by interactions between proteins that contain a RIP Homotypic Interaction Motif (RHIM). TRIF contains a RHIM sequence and can interact with receptor interacting protein kinases 1 (RIPK1) and 3 (RIPK3) to initiate necroptosis. Here, we demonstrate that the RHIM of TRIF is amyloidogenic and supports the formation of homomeric TRIF-containing fibrils. We show that the core tetrad sequence within the RHIM governs the supramolecular organisation of TRIF amyloid assemblies, although the stable amyloid core of TRIF amyloid fibrils comprises a much larger region than the conserved RHIM only. We provide evidence that RHIMs of TRIF, RIPK1 and RIPK3 interact directly to form heteromeric structures and that these TRIF-containing hetero-assemblies display altered and emergent properties that likely underlie necroptosis signalling in response to Toll-like receptor activation.

28 February 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
ACAlexandre Chappard
Alexandre Chappard
CLCraig Leighton
Craig Leighton
RSRebecca S. Saleeb
Rebecca S. Saleeb
KJKiani Jeacock
Kiani Jeacock
SBSarah R. Ball
Sarah R. Ball
MHMathew Horrocks
Mathew Horrocks
Protein misfolding and aggregation into oligomeric and fibrillar structures is a common feature of many neurogenerative disorders. Single‐molecule techniques have enabled characterization of these lowly abundant, highly heterogeneous protein aggregates, previously inaccessible using ensemble averaging techniques. However, they usually rely on the use of recombinantly‐expressed labeled protein, or on the addition of amyloid stains that are not protein‐specific. To circumvent these challenges, we have made use of a high affinity antibody labeled with orthogonal fluorophores combined with fast‐flow microfluidics and single‐molecule confocal microscopy to specifically detect α‐synuclein, the protein associated with Parkinson's disease. We used this approach to determine the number and size of α‐synuclein aggregates down to picomolar concentrations in biologically relevant samples.

17 November 2023 in Science Advances
Verified
Journal Article
Open access
RSRebecca S. Saleeb
Rebecca S. Saleeb
CLCraig Leighton
Craig Leighton
JLJi-Eun Lee
Ji-Eun Lee
JOJudi O’sHaughnessy
Judi O’sHaughnessy
KJKiani Jeacock
Kiani Jeacock
MHMathew Horrocks
Mathew Horrocks
Protein misfolding and aggregation is a characteristic of many neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease. The oligomers generated during aggregation are likely involved in disease pathogenesis and present promising biomarker candidates. However, owing to their small size and low concentration, specific tools to quantify and characterize aggregates in complex biological samples are still lacking. Here, we present single-molecule two-color aggregate pulldown (STAPull), which overcomes this challenge by probing immobilized proteins using orthogonally labeled detection antibodies. By analyzing colocalized signals, we can eliminate monomeric protein and specifically quantify aggregated proteins. Using the aggregation-prone alpha-synuclein protein as a model, we demonstrate that this approach can specifically detect aggregates with a limit of detection of 5 picomolar. Furthermore, we show that STAPull can be used in a range of samples, including human biofluids. STAPull is applicable to protein aggregates from a variety of disorders and will aid in the identification of biomarkers that are crucial in the effort to diagnose these diseases.

28 February 2023 in Angewandte Chemie
Verified
Journal Article
Open access
ACAlexandre Chappard
Alexandre Chappard
CLCraig Leighton
Craig Leighton
RSRebecca S. Saleeb
Rebecca S. Saleeb
KJKiani Jeacock
Kiani Jeacock
SBSarah R. Ball
Sarah R. Ball
MHMathew Horrocks
Mathew Horrocks
Protein misfolding and aggregation into oligomeric and fibrillar structures is a common feature of many neurogenerative disorders. Single‐molecule techniques have enabled characterization of these lowly abundant, highly heterogeneous protein aggregates, previously inaccessible using ensemble averaging techniques. However, they usually rely on the use of recombinantly‐expressed labeled protein, or on the addition of amyloid stains that are not protein‐specific. To circumvent these challenges, we have made use of a high affinity antibody labeled with orthogonal fluorophores combined with fast‐flow microfluidics and single‐molecule confocal microscopy to specifically detect α‐synuclein, the protein associated with Parkinson's disease. We used this approach to determine the number and size of α‐synuclein aggregates down to picomolar concentrations in biologically relevant samples.

23 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAlexander J. Dear
Alexander J. Dear
XTXiangyu Teng
Xiangyu Teng
SBSarah R. Ball
Sarah R. Ball
JLJoshua Lewin
Joshua Lewin
RHRobert I. Horne
Robert I. Horne
GMGeorg Meisl
Georg Meisl
The central hallmark of Parkinson’s disease pathology is the aggregation of the α -synuclein protein, which, in its healthy form, is associated with lipid membranes. Purified monomeric α -synuclein is relatively stable in vitro, but its aggregation can be triggered by the presence of lipid vesicles. Despite this central importance of lipids in the context of α -synuclein aggregation, their mechanistic role in this process has not been established to date. Here, we use chemical kinetics to develop a detailed mechanistic model that is able to globally describe the aggregation behaviour of α -synuclein in the presence of DMPS lipid vesicles, across a range of lipid and protein concentrations. Through the application of our kinetic model to experimental data, we find that the reaction is a co-aggregation process involving both protein and lipids and that lipids promote aggregation predominantly by enabling the elongation process. Moreover, we find that the initial formation of aggregates, via primary nucleation, takes place not on the surface of lipid vesicles but at the interfaces present in vitro. Our model will enable mechanistic insights, also in other lipid-protein co-aggregation systems, which will be crucial in the rational design of drugs that inhibit aggregate formation and act at the key points in the α -synuclein aggregation cascade.